Testing a new transcatheter valve for aortic valve narrowing
Part of Heart & circulation clinical trials.
This trial studies how safe and effective the NAVITOR valve is for treating narrowed aortic valves placed through a catheter (no open-heart surgery). It may be an option if you’re at intermediate-to-low surgical risk and meet heart ultrasound/CT measurements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a narrowed aortic valve (aortic valve stenosis) from valve wear over time
- Your surgery risk is intermediate or low (your heart team estimates your 30-day surgical death risk is <8%)
- You have heart symptoms classified as NYHA II, III, or IV
- Your expected life span is at least 2 years (or at least 1 year for some subgroups)
- You do NOT have certain recent heart events (like a heart attack in the past 30 days)
- You meet heart scan and anatomy needs (valve type, calcium, vessel size, and fit numbers for delivery)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares regular monitoring (“clinical surveillance”) versus replacing the aortic valve using a minimally invasive procedure called TAVR for people with moderate aortic stenosis. It aims to see which approach better reduces symptoms or heart damage over time.
This trial studies whether a new through-the-blood-vessel heart valve (TAVR) is safe and works well for people with severe aortic stenosis who are too risky for traditional surgery. If you qualify, you would be closely followed to check your symptoms and valve function over time.
This trial studies a faster, emergency version of a valve replacement done through the blood vessels (TAVI) for people with severe aortic valve narrowing. It aims to check whether this approach is safe and works when people are in urgent, hard-to-stabilize situations.
This trial tests a new heart valve replacement (TAVR) system in people with severe, symptomatic aortic stenosis. If you qualify, it may offer a less invasive option compared with open-heart valve surgery, while also helping researchers understand safety and early effectiveness.
This trial studies people with severe aortic valve disease who will receive a catheter-based valve replacement (TAVR). It aims to check how well this approach works for fixing a narrowed or leaky aortic valve, and to monitor outcomes afterward.
This trial tests a new heart valve device (Venus-Vitae) for people with severe aortic stenosis, a condition where the heart valve is too tight. It aims to see if the device works well for patients of all surgical risk levels.
Hear when a new Aortic Valve Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.